I t made no difference whether the pancreatic cancer patients received 5-fluorouracil (5-FU) plus leucovorin or gemcitabine after surgery: Overall survival, progressionfree survival, and quality of life were the same, according to the results of the European Study Group for Pancreatic Cancer (ESPAC3) trial, published in the Sept. 8 Journal of the American Medical Association . But for clinician...